Lenstec Inc. has announced its submission of the SBL- 3 IOL for Pre – Market Approval in the U.S.
The Lenstec SBL - 3 IOL (Segmented Bi-Focal Lens) is an asymmetric multifocal refractive IOL utilizing a 3 diopter add with a transition zone connecting the distance and near segments. It provides patients with near, intermediate and distance vision. In comparison to other available multifocal IOL’s, it shows a reduced occurrence of halos and glare and improved contrast sensitivity.
The SBL 3 has been widely used outside of the United State and has been found to be a valuable option for the refractive lens surgeon.
This is an exciting milestone for Lenstec and brings us closer to completing regulatory approval in the U.S. said Lenstec’s VP Sales and Marketing, Gary Lattanzio.
Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light on different parts of the retina for near, intermediate and distance vision.
Lenstec’s patented four-point fixation shape design, and 0.25 diopter power increments enable the best Effective Lens Positioning and Visual Outcomes possible.
Upon successful FDA approval, the SBL-3 would be the first Segmented Bi – Focal IOL in the U.S. market.
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.
More information about the SBL-3 and Lenstec’s line of Precision Series IOL’s is available at www.lenstec.com